Here's Why Shareholders Will Not Be Complaining About Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Pay Packet

Key Insights

• Bliss GVS Pharma's Annual General Meeting to take place on 31st of July
• CEO Gagan Sharma's total compensation includes salary of ₹24.1m
• Total compensation is similar to the industry average
• Bliss GVS Pharma's EPS grew by 76% over the past three years while total shareholder return over the past three years was 101%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

We have been pretty impressed with the performance at Bliss GVS Pharma Limited (NSE:BLISSGVS) recently and CEO Gagan Sharma deserves a mention for their role in it. The pleasing results would be something shareholders would keep in mind at the upcoming AGM on 31st of July. This would also be a chance for them to hear the board review the financial results, discuss future company strategy and vote on any resolutions such as executive remuneration. We think the CEO has done a pretty decent job and we discuss why the CEO compensation is appropriate.

View our latest analysis for Bliss GVS Pharma

Comparing Bliss GVS Pharma Limited's CEO Compensation With The Industry

According to our data, Bliss GVS Pharma Limited has a market capitalization of ₹16b, and paid its CEO total annual compensation worth ₹24m over the year to March 2025. We note that's an increase of 11% above last year. It is worth noting that the CEO compensation consists entirely of the salary, worth ₹24m.

For comparison, other companies in the Indian Pharmaceuticals industry with market capitalizations ranging between ₹8.6b and ₹35b had a median total CEO compensation of ₹24m. So it looks like Bliss GVS Pharma compensates Gagan Sharma in line with the median for the industry. Moreover, Gagan Sharma also holds ₹31m worth of Bliss GVS Pharma stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

Component	2025	2024	Proportion (2025)
Salary	₹24m	₹22m	100%
Other	-	-	-
Total Compensation	₹24m	₹22m	100%

Talking in terms of the industry, salary represented approximately 99% of total compensation out of all the companies we analyzed, while other remuneration made up 0.95087163% of the pie. Speaking on a company level, Bliss GVS Pharma prefers to tread along a traditional path, disbursing all compensation through a salary. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

Bliss GVS Pharma Limited's Growth

Bliss GVS Pharma Limited's earnings per share (EPS) grew 76% per year over the last three years. Its revenue is up 5.1% over the last year.

Shareholders would be glad to know that the company has improved itself over the last few years. It's also good to see modest revenue growth, suggesting the underlying business is healthy. While we don't have analyst forecasts for the company, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

Has Bliss GVS Pharma Limited Been A Good Investment?

We think that the total shareholder return of 101%, over three years, would leave most Bliss GVS Pharma Limited shareholders smiling. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

To Conclude...

Bliss GVS Pharma pays CEO compensation exclusively through a salary, with non-salary compensation completely ignored. The company's solid performance might have made most shareholders happy, possibly making CEO remuneration the least of the matters to be discussed in the AGM. In fact, strategic decisions that could impact the future of the business might be a far more interesting topic for investors as it would help them set their longer-term expectations.

While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. That's why we did some digging and identified 1 warning sign for Bliss GVS Pharma that you should be aware of before investing.

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.